ID   EM-3
AC   CVCL_2033
SY   EM3
DR   BTO; BTO:0005905
DR   CLO; CLO_0002923
DR   CLDB; cl1165
DR   Cell_Model_Passport; SIDM01046
DR   Cosmic; 787492
DR   Cosmic; 798662
DR   Cosmic; 994179
DR   Cosmic; 1026571
DR   DSMZ; ACC-134
DR   DSMZCellDive; ACC-134
DR   Wikidata; Q54832265
RX   CelloPub=CLPUB00038;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3332852;
RX   PubMed=3856862;
RX   PubMed=10071072;
RX   PubMed=10637496;
RX   PubMed=15843827;
RX   PubMed=25877200;
CC   Population: Caucasian.
CC   Doubling time: 2 days (CelloPub=CLPUB00038); ~40 hours (DSMZ=ACC-134).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D18S51: 13
ST   D19S433: 15,16
ST   D21S11: 30
ST   D2S1338: 22,24
ST   D3S1358: 14,16
ST   D5S818: 8,12
ST   D7S820: 10
ST   D8S1179: 14
ST   FGA: 21,22
ST   Penta D: 13,14
ST   Penta E: 7,16
ST   TH01: 9.3
ST   TPOX: 8,12
ST   vWA: 14,17
DI   NCIt; C7320; Childhood chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1196 ! EM-2
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   CelloPub=CLPUB00038;
RA   Keating A., Martin P.J., Bernstein I.D., Papayannopoulou T.,
RA   Raskind W., Singer J.W.;
RT   "EM-2 and EM-3: two new Ph1+ myeloid cell lines.";
RL   (In) Normal and neoplastic hematopoiesis, UCLA symposia on molecular and cellular biology, New Series Vol. 9; Golde D.W., Marks P.M. (eds.); pp.513-520; Alan R. Liss; New York (1983).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=3856862; DOI=10.1073/pnas.82.6.1810;
RA   Konopka J.B., Watanabe S.M., Singer J.W., Collins S.J., Witte O.N.;
RT   "Cell lines and clinical isolates derived from Ph1-positive chronic
RT   myelogenous leukemia patients express c-abl proteins with a common
RT   structural alteration.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1810-1814(1985).
//
RX   PubMed=10071072; DOI=10.1016/s0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=10637496; DOI=10.1038/sj.leu.2401604;
RA   Drexler H.G., Fombonne S., Matsuo Y., Hu Z.-B., Hamaguchi H.,
RA   Uphoff C.C.;
RT   "p53 alterations in human leukemia-lymphoma cell lines: in
RT   vitro artifact or prerequisite for cell immortalization?";
RL   Leukemia 14:198-206(2000).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//